Transforming Pharmaceutical Drug Discovery and Development- Recent Technological Advances
The last decade has seen rapid technological progress but with increasing demands for safe and efficacious drugs, technological solutions that reduce the barriers to clinical success will be of more interest than those that simply shift the bottlenecks and necessitate new compromises in the discovery and development process. Numerous problem areas remain: better information relative to disease pathophysiology is needed to improve target selection and validation; more predictive, biologically-relevant high throughput screens are essential; and, more emphasis must be placed on acquiring good ADME/Tox data earlier in the discovery process.
Central to overcoming these barriers are innovative technologies generating high-value information in a condensed timeframe to minimise the guesswork involved in target, lead and drug candidate selection like real-time quantitative polymerase chain reaction (real-time qPCR) which is the reference assay of choice; its high reproducibility and replication fidelity leads to a sensitivity, precision and dynamic range superior to current microarray or sequencing technologies.
Elimination of unsuccessful candidates earlier in the drug discovery process would help to reduce the resources consumed and high cost of bringing a drug to market. Due to the inherent slow throughput of MS-based techniques, ADME/Tox assays are typically pursued late in drug development. The use of high throughput MS systems have been extended to reduce bottlenecks in in vitro ADME assays such as CYP inhibition, metabolic stability and permeability, increasing throughput and capacity to allow for the processing of these samples much earlier in the drug discovery process.
As demands for safe and efficacious pharmaceutical drugs grow, technological solutions will be of increasing interest that reduces barriers to clinical success rather than simply shifting bottlenecks and necessitating new compromises in the discovery and development process.
The Journal of Pharmaceutical Chemistry and Pharmacology aims to disseminate knowledge and promote discussion through the publication of peer-reviewed, high quality research papers on all topics related to Pharmaceutical chemistry and pharmacology emphasizing on such technological advances which transform the pharmaceutical drug discovery and development process. The open access journal is published by Pulsus. Established in the year 1984, Pulsus was focusing on American region and presently expanding to healthcare informatics platform to the medical and pharma professionals throughout Europe, America, Asia, Australia and all other continents. Since its inception, Pulsus received the endorsements of the medical associations and industries of the international reputation. This support allowed Pulsus Group to gain excellent reputation from the scientific and industrial community and able to bridge relations between industries and practicing physicians.
The Journal emphasizes on quality research education and development. Original research articles, reviews, short communications, and letters to the editors in the fields of pharmaceutical chemistry, medicinal chemistry and pharmacology are accepted. Every effort is made to have a quality, rigorous, critical peer-review and rapid publishing process.
With immense pleasure we cordially invite scientists, academicians and researchers from around the world to contribute their current research undertakings to our upcoming issue (Volume 4| Issue 1) on behalf of Editor-in-Chief.
Associate Managing Editor
Journal of Pharmaceutical Chemistry and Pharmacology